Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus extension: a multi-institutional retrospective study in Japan

Authors: Masanori Hirono, Mikio Kobayashi, Tomoyasu Tsushima, Wataru Obara, Nobuo Shinohara, Keiichi Ito, Masatoshi Eto, Tatsuya Takayama, Yasuhisa Fujii, Masaharu Nishikido, Go Kimura, Takeshi Kishida, Masayuki Takahashi, Noriomi Miyao, Yukio Naya, Takashige Abe, Tomoaki Fujioka, Kazuto Ito, Seiji Naito, Members of the Japanese Society of Renal Cancer

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Although the percentage of patients with renal cell carcinoma (RCC) extending into venous systems is unexpectedly high, the prognostic impact and independency of venous tumor thrombus-related factors on overall survival (OS) remain controversial. Furthermore, the prognostic impact of various clinicopathologic factors including tumor thrombus-related factors on OS may change with elapsed years after the intervention and also with follow-up duration of participants. The aim of the study is to explore independent and universal predictive preoperative and intraoperative clinicopathologic factors on OS in patients with RCC extending into venous systems using subgroup analysis in terms of restricted follow-up duration and yearly-based survivors.

Methods

Between 1980 and 2009, 292 patients diagnosed with RCC with venous tumor thrombus were retrospectively registered for this study. The prognostic impacts of various clinicopathologic and surgical treatment factors including levels of venous thrombus, venous wall invasion status and likelihood of aggressive cytoreductive operation, were investigated using Kaplan-Meier method and following multivariate Cox proportional hazards model for all patients and those still alive at 1, 2, and 3 years of follow-up. To investigate the impact of follow-up duration on the statistical analyses, multivariate logistic regression analyses were used to explore prognostic factors using restricted data until 1, 2, and 3 years of follow-up.

Results

The median follow-up duration was 40.4 months. The 5-year OS was 47.6%. Several independent predictive factors were identified in each subgroup analysis in terms of yearly-based survival and restricted follow-up duration. The presence of tumor thrombus invading to venous wall was independently related to OS in the full-range follow-up data and in survivors at 2 and 3 years of follow-up. Using restricted follow-up data until 1, 2, and 3 years of follow-up, many independent predictive factors changed with follow-up duration, but surgical category could be universal and independent predictive factors.

Conclusion

The most universal factors affecting improvement both in short-term and long-term survivals could be cytoreductive surgery and absence of venous wall invasion. It may mean that feasible aggressive cytoreductive operation following more reliable preoperative imaging for predicting venous wall invasion status would improve OS for patients with RCC extending into venous systems.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pagano F, Dal Bianco M, Artibani W, et al: Renal cell carcinoma with extension into the inferior vena cava: problems in diagnosis, staging and treatment. Eur Urol. 1992, 22: 200-203.PubMed Pagano F, Dal Bianco M, Artibani W, et al: Renal cell carcinoma with extension into the inferior vena cava: problems in diagnosis, staging and treatment. Eur Urol. 1992, 22: 200-203.PubMed
2.
go back to reference Casanova GA, Zingg EJ: Inferior vena caval tumor extension in renal cell carcinoma. Urol Int. 1991, 47: 216-218. 10.1159/000282225.CrossRefPubMed Casanova GA, Zingg EJ: Inferior vena caval tumor extension in renal cell carcinoma. Urol Int. 1991, 47: 216-218. 10.1159/000282225.CrossRefPubMed
3.
go back to reference Hatcher PA, Anderson EE, Paulson DF, et al: Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol. 1991, 145: 20-23.PubMed Hatcher PA, Anderson EE, Paulson DF, et al: Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol. 1991, 145: 20-23.PubMed
4.
go back to reference Hoehn W, Hermanek P: Invasion of veins in renal cell carcinoma - frequency, correlation and prognosis. Eur Urol. 1983, 9: 276-280.PubMed Hoehn W, Hermanek P: Invasion of veins in renal cell carcinoma - frequency, correlation and prognosis. Eur Urol. 1983, 9: 276-280.PubMed
5.
go back to reference Klatte T, Pantuck AJ, Riggs SB, et al: Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol. 2007, 178: 1189-1195. 10.1016/j.juro.2007.05.134.CrossRefPubMed Klatte T, Pantuck AJ, Riggs SB, et al: Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol. 2007, 178: 1189-1195. 10.1016/j.juro.2007.05.134.CrossRefPubMed
6.
go back to reference Kim HL, Zisman A, Han KR, et al: Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different?. J Urol. 2004, 171: 588-591. 10.1097/01.ju.0000104672.37029.4b.CrossRefPubMed Kim HL, Zisman A, Han KR, et al: Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different?. J Urol. 2004, 171: 588-591. 10.1097/01.ju.0000104672.37029.4b.CrossRefPubMed
7.
go back to reference Al Otaibi M, Abou Youssif T, Alkhaldi A, et al: Renal cell carcinoma with inferior vena caval extension: impact of tumour extent on surgical outcome. BJU Int. 2009, 104: 1467-1470. 10.1111/j.1464-410X.2009.08575.x.CrossRefPubMed Al Otaibi M, Abou Youssif T, Alkhaldi A, et al: Renal cell carcinoma with inferior vena caval extension: impact of tumour extent on surgical outcome. BJU Int. 2009, 104: 1467-1470. 10.1111/j.1464-410X.2009.08575.x.CrossRefPubMed
8.
go back to reference Wagner B, Patard JJ, Méjean A, et al: Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol. 2009, 55: 452-459. 10.1016/j.eururo.2008.07.053.CrossRefPubMed Wagner B, Patard JJ, Méjean A, et al: Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol. 2009, 55: 452-459. 10.1016/j.eururo.2008.07.053.CrossRefPubMed
9.
go back to reference Blute ML, Leibovich BC, Lohse CM, et al: The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int. 2004, 94: 33-41. 10.1111/j.1464-410X.2004.04897.x.CrossRefPubMed Blute ML, Leibovich BC, Lohse CM, et al: The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int. 2004, 94: 33-41. 10.1111/j.1464-410X.2004.04897.x.CrossRefPubMed
10.
go back to reference Marshall VF, Middleton RG, Holswade GR, et al: Surgery for renal cell carcinoma in the vena cava. J Urol. 1970, 103: 414-420.PubMed Marshall VF, Middleton RG, Holswade GR, et al: Surgery for renal cell carcinoma in the vena cava. J Urol. 1970, 103: 414-420.PubMed
11.
go back to reference Skinner DG, Colvin RB, Vermillion CD, et al: Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer. 1971, 28: 1165-1177. 10.1002/1097-0142(1971)28:5<1165::AID-CNCR2820280513>3.0.CO;2-G.CrossRefPubMed Skinner DG, Colvin RB, Vermillion CD, et al: Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer. 1971, 28: 1165-1177. 10.1002/1097-0142(1971)28:5<1165::AID-CNCR2820280513>3.0.CO;2-G.CrossRefPubMed
12.
go back to reference Skinner DG, Pfister RF, Colvin R: Extension of renal cell carcinoma into the vena cava: the rationale for aggressive surgical management. J Urol. 1972, 107: 711-716.PubMed Skinner DG, Pfister RF, Colvin R: Extension of renal cell carcinoma into the vena cava: the rationale for aggressive surgical management. J Urol. 1972, 107: 711-716.PubMed
13.
go back to reference Skinner DG, Pritchett TR, Lieskovsky G, et al: Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival. Ann Surg. 1989, 210: 387-392. 10.1097/00000658-198909000-00014.CrossRefPubMedPubMedCentral Skinner DG, Pritchett TR, Lieskovsky G, et al: Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival. Ann Surg. 1989, 210: 387-392. 10.1097/00000658-198909000-00014.CrossRefPubMedPubMedCentral
14.
go back to reference Ficarra V, Righetti R, D’Amico A, et al: Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma. Oncology. 2001, 61: 10-15. 10.1159/000055346.CrossRefPubMed Ficarra V, Righetti R, D’Amico A, et al: Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma. Oncology. 2001, 61: 10-15. 10.1159/000055346.CrossRefPubMed
15.
go back to reference Glazer AA, Novick AC: Long-term follow up after surgical treatment for renal cell carcinoma extending into the right atrium. J Urol. 1996, 155: 448-450. 10.1016/S0022-5347(01)66415-2.CrossRefPubMed Glazer AA, Novick AC: Long-term follow up after surgical treatment for renal cell carcinoma extending into the right atrium. J Urol. 1996, 155: 448-450. 10.1016/S0022-5347(01)66415-2.CrossRefPubMed
16.
go back to reference Sosa RE, Muecke EC, Vaughan ED, et al: Renal cell carcinoma extending into the inferior vena cava: the prognostic significance of the level of vena caval involvement. J Urol. 1984, 132: 1097-1100.PubMed Sosa RE, Muecke EC, Vaughan ED, et al: Renal cell carcinoma extending into the inferior vena cava: the prognostic significance of the level of vena caval involvement. J Urol. 1984, 132: 1097-1100.PubMed
17.
go back to reference Bissada NK, Yakout HH, Babanouri A, et al: Long-term experience with management of renal cell carcinoma involving the inferior vena cava. Urology. 2003, 61: 9-92.CrossRef Bissada NK, Yakout HH, Babanouri A, et al: Long-term experience with management of renal cell carcinoma involving the inferior vena cava. Urology. 2003, 61: 9-92.CrossRef
18.
go back to reference Libertino JA, Zinman L, Watkins E: Long-term results of resection of renal cell cancer with extension into inferior vena cava. J Urol. 1987, 137: 21-24.PubMed Libertino JA, Zinman L, Watkins E: Long-term results of resection of renal cell cancer with extension into inferior vena cava. J Urol. 1987, 137: 21-24.PubMed
19.
go back to reference Moinzadeh A, Libertino JA: Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same?. J Urol. 2004, 171: 598-601. 10.1097/01.ju.0000108842.27907.47.CrossRefPubMed Moinzadeh A, Libertino JA: Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same?. J Urol. 2004, 171: 598-601. 10.1097/01.ju.0000108842.27907.47.CrossRefPubMed
20.
go back to reference Tanaka M, Fujimoto K, Okajima E, et al: Prognostic factors of renal cell carcinoma with extension into inferior vena cava. Int J Urol. 2008, 15: 394-398. 10.1111/j.1442-2042.2008.02017.x.CrossRefPubMed Tanaka M, Fujimoto K, Okajima E, et al: Prognostic factors of renal cell carcinoma with extension into inferior vena cava. Int J Urol. 2008, 15: 394-398. 10.1111/j.1442-2042.2008.02017.x.CrossRefPubMed
21.
go back to reference Zisman A, Wieder JA, Pantuck AJ, et al: Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol. 2003, 169: 909-916. 10.1097/01.ju.0000045706.35470.1e.CrossRefPubMed Zisman A, Wieder JA, Pantuck AJ, et al: Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol. 2003, 169: 909-916. 10.1097/01.ju.0000045706.35470.1e.CrossRefPubMed
22.
go back to reference Haferkamp A, Bastian PJ, Jakobi H, et al: Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term follow up. J Urol. 2007, 177: 1703-1708. 10.1016/j.juro.2007.01.039.CrossRefPubMed Haferkamp A, Bastian PJ, Jakobi H, et al: Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term follow up. J Urol. 2007, 177: 1703-1708. 10.1016/j.juro.2007.01.039.CrossRefPubMed
23.
go back to reference Ficarra V, Novara G, Iafrate M, et al: Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome. Eur Urol. 2007, 51: 722-729. 10.1016/j.eururo.2006.07.010.CrossRefPubMed Ficarra V, Novara G, Iafrate M, et al: Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome. Eur Urol. 2007, 51: 722-729. 10.1016/j.eururo.2006.07.010.CrossRefPubMed
24.
go back to reference Thompson RH, Leibovich BC, Cheville JC, et al: Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a?. J Urol. 2005, 173: 918-921. 10.1097/01.ju.0000153419.98715.24.CrossRefPubMed Thompson RH, Leibovich BC, Cheville JC, et al: Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a?. J Urol. 2005, 173: 918-921. 10.1097/01.ju.0000153419.98715.24.CrossRefPubMed
25.
go back to reference Moch H, Artibani W, Delahunt B, et al: Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol. 2009, 56: 636-643. 10.1016/j.eururo.2009.06.036.CrossRefPubMed Moch H, Artibani W, Delahunt B, et al: Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol. 2009, 56: 636-643. 10.1016/j.eururo.2009.06.036.CrossRefPubMed
26.
go back to reference Thompson RH, Leibovich BC, Cheville JC, et al: Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?. J Urol. 2005, 174: 1218-1221. 10.1097/01.ju.0000173942.19990.40.CrossRefPubMed Thompson RH, Leibovich BC, Cheville JC, et al: Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?. J Urol. 2005, 174: 1218-1221. 10.1097/01.ju.0000173942.19990.40.CrossRefPubMed
27.
go back to reference Leibovich BC, Cheville JC, Lohse CM, et al: Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved?. J Urol. 2005, 173: 716-719. 10.1097/01.ju.0000151830.27750.d2.CrossRefPubMed Leibovich BC, Cheville JC, Lohse CM, et al: Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved?. J Urol. 2005, 173: 716-719. 10.1097/01.ju.0000151830.27750.d2.CrossRefPubMed
28.
go back to reference Ficarra V, Galfano A, Guillé F, et al: A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients. J Urol. 2007, 178: 418-424. 10.1016/j.juro.2007.03.104.CrossRefPubMed Ficarra V, Galfano A, Guillé F, et al: A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients. J Urol. 2007, 178: 418-424. 10.1016/j.juro.2007.03.104.CrossRefPubMed
Metadata
Title
Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus extension: a multi-institutional retrospective study in Japan
Authors
Masanori Hirono
Mikio Kobayashi
Tomoyasu Tsushima
Wataru Obara
Nobuo Shinohara
Keiichi Ito
Masatoshi Eto
Tatsuya Takayama
Yasuhisa Fujii
Masaharu Nishikido
Go Kimura
Takeshi Kishida
Masayuki Takahashi
Noriomi Miyao
Yukio Naya
Takashige Abe
Tomoaki Fujioka
Kazuto Ito
Seiji Naito
Members of the Japanese Society of Renal Cancer
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-447

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine